MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/hon.3222

Медицинская библиотека · Hematological oncology · 2023

Venetoclax in biomarker-selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety.

Badawi Mohamed, Coppola Sheryl, Eckert Doerthe, Gopalakrishnan Sathej, Engelhardt Benjamin, Doelger Eva, Huang Weize, Dobkowska Edyta, Kumar Shaji, Menon Rajeev M, Salem Ahmed Hamed

Клиническое исследование II фазыКлиническое исследование I фазыСтатьяПеревод в очереди

Аннотация

Venetoclax, a potent BCL-2 inhibitor, is currently under development for treatment of t(11;14) Multiple myeloma (MM). The objective of this research was to investigate the exposure-response relationships of venetoclax for a phase 1/2 study evaluating venetoclax monotherapy or in combination with dexamethasone in relapsed or refractory MM. A total of 117 patients receiving venetoclax at 300, 600, 800, 900, or 1200 mg were included in the analysis. The impact of venetoclax exposures on efficacy (objective response rate [ORR], progression-free survival [PFS] and overall survival [OS]) as well as safety (treatment-emergent adverse effects (grade ≥3) of neutropenia, infection, and any grade of serious treatment-emergent adverse effects) was evaluated. In the t(11;14)-positive subpopulation, venetoclax exposure relationships to PFS and OS indicated a trend of longer PFS and OS with higher exposures. Moreover, logistic regression analyses for clinical response (ORR and ≥VGPR rate) demonstrated a statistically significant (p < 0.05) relationship with exposure. Evaluation of the exposure-safety relationships demonstrated a lack of a relationship between venetoclax exposures (AUCavg ) and grade ≥3 infections, grade ≥3 neutropenia, grade ≥3 treatment-emergent adverse events or any grade serious treatment-emergent adverse events. These findings support further study of venetoclax at 800 mg QD dose in combination with dexamethasone in the t(11;14)-positive patient population where increased efficacy was observed without an increase in safety events.Clinical Trial: NCT01794520 registered 20 February 2013.

Для цитирования: Badawi Mohamed, Coppola Sheryl, Eckert Doerthe, Gopalakrishnan Sathej, Engelhardt Benjamin, Doelger Eva, Huang Weize, Dobkowska Edyta, Kumar Shaji, Menon Rajeev M, Salem Ahmed Hamed. Venetoclax in biomarker-selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety.. Hematological oncology. 2023. DOI: 10.1002/hon.3222.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.